Genomics is used to diagnose diseases, guide cancer treatment, track outbreaks, develop safer drug prescriptions, improve agriculture, and screen newborns for hundreds of genetic conditions. Unlike genetics, which focuses on single genes and inheritance, genomics looks at all of a person’s genes at once, including how they interact with each other and with environmental factors. That broader view has made it one of the most versatile tools in modern science and medicine.
Matching Cancer Treatment to Tumor DNA
One of the most impactful uses of genomics is in oncology, where doctors sequence the DNA of a patient’s tumor to find specific mutations driving its growth. Instead of relying solely on the cancer’s location in the body, treatment can be matched to its molecular profile. This approach, called comprehensive genomic profiling, has shown measurable survival benefits across multiple cancer types.
In patients with advanced gastroesophageal cancer, matching targeted therapies to tumor profiles extended median overall survival from 9.0 months with standard treatment to 15.7 months. For metastatic gastric cancer, patients who received biomarker-driven therapy survived a median of 9.8 months compared to 6.9 months on conventional treatment. These aren’t small differences when measured in months of life.
The degree of molecular matching matters. When researchers scored how closely a patient’s treatment aligned with their tumor’s genomic profile, those with high matching scores (above 50%) had significantly longer periods before their cancer progressed, roughly double the time compared to patients with low matching scores (6.5 versus 3.1 months). In ovarian cancer patients with a specific BRCA gene mutation, targeted therapy kept the disease stable for a median of 16.6 months compared to 5.4 months with placebo. Across studies, treatments guided by molecular profiling yielded 30 to 56% more benefit in slowing disease progression than prior unguided therapies.
Diagnosing Rare Diseases
For families searching for answers to unexplained symptoms, genomics has become a powerful diagnostic tool. Many rare diseases are caused by genetic variants that traditional testing misses. Whole genome sequencing reads nearly all of a person’s DNA, casting a much wider net than older methods that examine only the protein-coding portions of genes (called exome sequencing).
A meta-analysis of over 1,600 pediatric patients found that whole genome sequencing identified the cause of disease in 7% more patients after exome sequencing had already come back negative. The total diagnostic yield of genome sequencing in those same patients reached about 24%, meaning roughly one in four children who had gone undiagnosed finally received a molecular explanation. For families who have often spent years cycling through specialists without answers, that number represents a real turning point.
Preventing Drug Side Effects
People metabolize medications at different rates depending on their genetic makeup. Genomics helps identify which patients are likely to have dangerous reactions to specific drugs or need adjusted doses. The FDA maintains a formal table of gene-drug interactions that clinicians can reference before prescribing.
- Abacavir (an HIV medication): Patients carrying a specific immune-system gene variant face severe hypersensitivity reactions. Genetic testing before prescribing is now standard, and positive results mean the drug should not be used.
- Warfarin (a blood thinner): Variants in a liver enzyme gene alter how quickly the body processes the drug, requiring individualized starting doses to avoid dangerous bleeding or clotting.
- Azathioprine (an immunosuppressant): Patients who metabolize the drug slowly accumulate toxic levels, risking a severe drop in blood cell counts. Poor metabolizers may need an entirely different medication.
- Aripiprazole (a psychiatric medication): Slow metabolizers end up with higher blood concentrations, increasing the risk of side effects. Dose adjustments based on genetic testing help avoid this.
This field, known as pharmacogenomics, looks at variations across multiple genes rather than just one. Because drug response is often influenced by several genes simultaneously, a genome-wide view provides a more complete picture than testing a single gene in isolation.
Tracking Disease Outbreaks in Real Time
Genomics has become essential for public health surveillance. By sequencing the DNA or RNA of pathogens, scientists can track how viruses and bacteria mutate, where outbreaks originated, and how they spread across borders.
During the COVID-19 pandemic, genomic surveillance monitored viral evolution, identified new variants, and informed updates to vaccines and diagnostics. But the applications go well beyond a single pandemic. Sequencing of dengue virus strains in various outbreaks revealed that some clustered with viruses from India while others matched a strain from China, tracing transmission to international travel. In Europe, genomic analysis showed that West Nile virus had been independently introduced at least 13 times, with specific lineages dominating in particular regions.
For foodborne illness, whole genome sequencing has transformed outbreak investigations. Sequencing Salmonella, Listeria, Campylobacter, and E. coli strains allows health agencies to pinpoint outbreak sources, differentiate between localized and widespread contamination, and map transmission routes. During outbreaks of hemolytic uremic syndrome caused by Shiga toxin-producing E. coli, real-time sequencing has helped distinguish between separate outbreaks and trace contaminated food products, steps that directly reduce serious illness and death, particularly in children.
Screening Newborns for Hundreds of Conditions
Standard newborn screening in the U.S. tests for a few dozen conditions using blood spot samples collected shortly after birth. Genomic newborn screening is expanding that number dramatically. The Early Check program in North Carolina, one of several pilot programs now underway, uses genome sequencing on the same dried blood spots to analyze 169 high-actionability genes, covering conditions where early intervention during the first two years of life can make a meaningful difference. An additional 29 genes with somewhat lower actionability are offered as optional. All conditions on the federally recommended screening panel that can be detected through sequencing are included.
Improving Crops and Livestock
Genomics is used in agriculture to accelerate breeding programs for both plants and animals. Rather than selecting for desirable traits over many generations based on physical observation alone, breeders can use genomic data to identify animals or plants carrying favorable gene combinations and select them much earlier in the process.
The cattle industry has been one of the biggest beneficiaries of genomic selection, using it to improve milk production, disease resistance, and other economically important traits in fewer generations than traditional breeding allows. Aquaculture has similarly adopted genomic selection, particularly for breeding disease-resistant fish. In crops, researchers are applying genomic prediction methods to traits like drought tolerance in grapevines, aiming to develop varieties that can withstand changing climate conditions.
Consumer DNA Tests and Their Limits
Direct-to-consumer genomic tests have made it possible for anyone to receive genetic risk information without a doctor’s order. But these tests are not diagnostic and cover only a fraction of what clinical-grade sequencing analyzes. For example, one major consumer test reports on just one variant in each of two genes linked to Parkinson’s disease. Clinical diagnostic tests, by contrast, sequence the full coding regions of all genes known to be associated with a condition.
The raw data that consumer tests provide is particularly unreliable. An analysis found a 40% false-positive rate in genes with potential clinical significance in raw genotyping data from consumer testing companies, along with multiple cases where third-party interpretation services misclassified variants. These files typically come with disclaimers noting the data is not validated for accuracy or intended for medical use, but many consumers overlook that fine print.
Falling Costs and Legal Protections
The cost barrier to genomics has collapsed. Sequencing a whole human genome cost roughly $100 million in 2001. By 2023, it had fallen to just over $500, and more recent estimates put it around $350, with projections that it could eventually reach as low as $10. That price drop is what makes applications like routine newborn screening and population-wide pharmacogenomic testing feasible.
As genomic data becomes more accessible, legal protections matter. In the U.S., the Genetic Information Nondiscrimination Act (GINA) prohibits health insurers from using genetic information to set premiums, deny coverage, or impose preexisting condition exclusions. It also bars employers with 15 or more employees from using genetic data in hiring, compensation, or other employment decisions. However, GINA does not extend to life insurance, disability insurance, or long-term care insurance. And it only covers genetic information, not conditions that have already manifested. If a genetic predisposition has developed into a diagnosed disease, insurers and employers can factor that diagnosis into their decisions.